Corcept Therapeutics (CORT) Tops Q3 EPS by 5c; Reaffirms
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Corcept Therapeutics Announces Third Quarter 2018 Financial Results and Provides Corporate Update
November 1, 2018 4:05 PM EDTMENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended September 30, 2018.
Financial Highlights
Revenue of $64.4 million, a 51 percent increase from third quarter 2017GAAP net income of $0.14 per share, compared to $0.11 per share in third quarter 2017Non-GAAP net income of $0.22 per share, compared to... More